Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Janet Haniak
While leading large pharma with seven out-licensing or divestiture deals apiece during 2018, AstraZeneca and Novartis each slowed their pace somewhat. But several peer companies followed suit, as there were 31 such deals among the 20 largest biopharma firms last year.